Diploma

UMEDICA is a part of the Amoli Group of Companies, manufacturing and exporting a wide range of formulations viz; Injectables, Tablets, Capsules, Suspensions, Dry Syrups, etc. UMEDICA offers a diverse product portfolio comprising of antibiotics, non-steroidal anti-inflammatory (NSAIDs), analgesics, antifungal, antiviral, anti-malarials, antituberculosis agents, antihistaminics, psychotropic, antihypertensives, lipid-lowering agents, drugs for sexual dysfunction, multivitamins etc.

MLSP aims to be the leading manufacturer of generic API’s and fine chemicals. Our focus is on complying with cGMP guidelines and building towards developing into a world class manufacturing facility by providing safe and healthy workplace.  Our company is growing steadily; recently, in 2019, we have started a new Production Unit with 52 reactors and advanced equipment in order to satisfy the unmet needs of the pharmaceutical companies.

Amneal Pharmaceuticals, Inc is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.  Today’s healthcare environment requires a new approach and new ideas. While staying true to our reputation for quality, service and value, we are reinventing our processes, our playbook and our creative partnerships.

Post : Operator/Assistant/Associate - 50 posts

Intas Pharmaceuticals Ltd. Experience spanning three decades in healthcare, with a wide range of formulations to meet the needs of ailing humanity, Intas Pharmaceuticals headquartered at Ahmedabad (India), is now a force to reckon with, in the global pharma horizon. With expertise in a range of formulations, from tablets to injectables to newer drug delivery systems, Intas is currently ranked 17th among the Indian Pharma majors. A variety of initiatives in Research and Development, patents and ANDA filing, NDDS, quality manufacturing support, along with approvals by regulatory authorities of many countries has made Intas a global healthcare provider.

Post : Officer / Senior Officer - 15 posts

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India. Intas' success and incessant growth lies in clinical execution of successful and strategic moves made in the areas of manufacturing, R&D, Biotechnology and global operations over three decades.

Teva is a global pharmaceutical leader and the world's largest generic medicines producer, committed to improving health and increasing access to quality health solutions worldwide. Our employees are at the core of our success, with colleagues in over 80 countries delivering the world's largest medicine cabinet to 200 million people every day. We offer a uniquely diverse portfolio of products and solutions for patients and we've built a promising pipeline centered around our core therapeutic areas.

Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs nearly 6000 people in over 80 countries.

Aurobindo Pharma Ltd., is a Leading Pharmaceutical company having 23 plants worldwide with regulatory approvals from USFDA, UK MHRA etc. with a turnover of more than $2.5 billion dollars.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top six pharmaceutical companies in India. Through our sales and marketing headquarters in Baltimore, MD, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies.